Zentalis Pharmaceuticals, Inc. — Operating Income by Fiscal Year
7 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/90580bea-229b-43eb-85ab-1410a04f3b45/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-152.8M | 2025-01-01 – 2025-12-31 | evidence 0001725160-26-000014 |
| FY 2024 | $-191.2M | 2024-01-01 – 2024-12-31 | evidence 0001725160-25-000067 |
| FY 2023 | $-299.5M | 2023-01-01 – 2023-12-31 | evidence 0001725160-24-000080 |
| FY 2022 | $-227.3M | 2022-01-01 – 2022-12-31 | evidence 0001725160-23-000048 |
| FY 2021 | $-216.5M | 2021-01-01 – 2021-12-31 | evidence 0001725160-22-000053 |
| FY 2020 | $-118.8M | 2020-01-01 – 2020-12-31 | evidence 0001725160-21-000075 |
| FY 2019 | $-46.8M | 2019-01-01 – 2019-12-31 | evidence 0001725160-21-000075 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Zentalis Pharmaceuticals, Inc. — all facts · Revenue · Net Income